Skip to main content
. 2020 Aug 21;10(23):10548–10562. doi: 10.7150/thno.46826

Figure 5.

Figure 5

The presence of NfsA_Ec is predictive of PR-104 efficacy in vivo. A and B) The in vivo relationship between EF5 reduction, pimonidazole reduction and cell kill from PR-104. Tumours composed of 0-40% NfsA_Ec cells were grown in NIH-III mice and excised when the tumours reached a mean diameter of 10mm. Prior to excision, mice were dosed with 562 μmol/kg PR-104 followed by 30 mg/kg EF5 two hours later. Tumour cells were treated with 20 µM pimonidazole ex vivo for two hours before being labelled for both EF5 and pimonidazole adducts and plated to obtain a clonogenic endpoint for cell kill from PR-104. C and D) In vivo efficacy of PR-104 in 22% NfsA_Ec-expressing tumour xenografts. Average tumour volume and Kaplan-Meier survival plots for 100% WT and 22% NfsA_Ec/78% WT HCT116 xenografts grown subcutaneously on NIH-III mice and treated with PR-104 (1000 µmol/kg) or vehicle. N= 8-11 per group.